Picamilon

Picamilon is a Soviet-era prescription drug, made by chemically bonding GABA to niacin so the molecule can cross the blood-brain barrier. Most people take it as a low-key anxiolytic, something that takes the edge off without sedating you, while also nudging cerebral blood flow up. The typical use case is acute stress, performance anxiety, asthenia (that wrung-out, low-energy state after prolonged stress or illness), or to keep a stimulant stack from feeling jittery.

It sits in a middle ground between a stimulant and a tranquiliser. At 50-100 mg it tends to feel calm and slightly more focused, at 150-300 mg it leans more sedating. Effects come on in 30-60 minutes and last 4-6 hours. It's a daytime tool, not a sleep aid, and not something that builds dependence the way phenibut does.

the evidence base is mostly Russian, mostly older, and mostly in patient populations rather than healthy people. A 2023 FDA assay found picamilon itself doesn't bind to GABA receptors or any of 49 other targets tested, which means whatever effect you feel comes from the GABA and niacin it releases after hydrolysis, not from the parent molecule. It's prescription-only in Russia and the FDA has classified it as an unapproved drug in the US since 2015, so it sits outside any standard supplement framework.

Deep-dive

Picamilon is N-nicotinoyl-GABA, a synthetic conjugate where niacin (vitamin B3) is amide-bonded to GABA. The point of the bond is solubility, GABA on its own is too polar to cross the blood-brain barrier in meaningful amounts, while picamilon is lipophilic enough to diffuse across. Once inside, esterases and amidases hydrolyse the amide bond and free GABA and niacin separately. Plasma concentrations peak within an hour after a 50-200 mg dose and the half-life sits around 1-2 hours. Roughly 50-88% bioavailability, mostly excreted unchanged by the kidneys.

The 2023 FDA assay matters. Santillo and Sprando screened picamilon against 50 safety-related targets, including GABA-A, GABA-B, GABA transporters, calcium channels, and a long list of other receptors and enzymes. At 10 μM, picamilon was inactive at all of them. Other GABA analogues like baclofen, pregabalin, and vigabatrin all bind something on that panel. Picamilon doesn't. The interpretation is that any clinical effect is downstream of hydrolysis, the GABA and niacin freed in the brain do the work, the parent molecule is essentially a delivery vehicle. This matters because it means dose-response, onset, and side effect profile track with the released GABA and niacin, not with some unique receptor activity of picamilon itself.

The GABA side. Once liberated in the CNS, GABA acts on GABA-A and GABA-B receptors and dampens neuronal firing. The clinical phenotype people report (calm focus, less anxiety, no sedation at low doses) is consistent with mild GABAergic tone rather than the heavy GABA-A α1 binding you'd see with a benzo or phenibut. There's no evidence picamilon causes the kind of physical dependence or withdrawal seen with phenibut, partly because the GABA load delivered per dose is modest and the half-life is short.

The niacin side. Niacin is a vasodilator. The amount of niacin freed from a 100 mg picamilon dose is roughly 35 mg of niacin equivalent, well below the threshold where you'd typically see strong flushing, but enough to nudge cerebral blood flow up. Russian work has consistently shown picamilon increases cerebrovascular flow and reduces vascular resistance. This is probably the mechanism behind the cerebrovascular insufficiency indication and the migraine prophylaxis use. It's also why some people get mild flushing or warmth at higher doses.

Clinical evidence. The evidence base is real but skewed. The largest Russian dataset covers 984 patients across multiple indications, with daily doses from 40-300 mg and courses from 2 weeks to 1.5 months. The findings most relevant to healthy users are anxiolytic and anti-asthenic effects at 40-80 mg/day and improved cognitive recovery after stress or alcohol withdrawal. A 2024 open cohort study in 50 patients with chronic cerebral ischemia used 200 mg IV for 10 days then 50 mg three times daily for 60 days, and reported improvements in MoCA scores, sleep quality, and endothelial markers (reduced ADMA). A 2022 trial in 278 patients found picamilon plus ginkgo outperformed ginkgo alone for vascular cognitive impairment. None of these studies are placebo-controlled in the modern sense and most are in older patients with cerebrovascular disease, not healthy adults. There's no strong evidence picamilon enhances cognition in already-healthy people.

Where it actually shines. Acute anxiolysis without sedation, smoothing the edge off a stimulant stack, and supporting recovery from prolonged stress (the asthenia indication is the closest thing to what most users are actually treating). It's also reasonable for situational performance anxiety, public speaking, exam-day nerves, social situations, where you want anxiolysis without slowing down.

Where it doesn't. As a standalone nootropic for healthy people there's no good evidence it sharpens cognition. As a sleep aid it's too short-acting and not sedating enough at typical doses. As a daily anxiolytic it probably works for some people but the long-term safety data is thin and the regulatory status means quality control on supply is unreliable.

Women. No human studies have stratified picamilon effects by sex, and the Russian patient cohorts have included both men and women without reporting sex-specific outcomes. The relevant biology is GABA system dynamics across the female lifespan. Cortical GABA tone fluctuates with the menstrual cycle, drops during the mid-follicular phase and again in pregnancy and the postpartum period, and shifts again across perimenopause. In practice this means picamilon's anxiolytic effect may feel more pronounced in low-GABA-tone phases (late luteal PMS, perimenopausal anxiety) and less so when allopregnanolone is high. There's no female-specific dose adjustment in the Russian prescribing information. Avoid in pregnancy and breastfeeding, the Russian label lists both as contraindications and there is no human safety data.

Older adults. The bulk of the Russian clinical use is actually in adults over 50 with cerebrovascular insufficiency or late-life depression, where 60-150 mg/day for 1-3 months is standard. If you're older and considering it for cognitive complaints, get baseline workup for actual cerebrovascular and metabolic causes first, picamilon isn't a substitute for treating hypertension, atrial fibrillation, or sleep apnoea.

Limits of the evidence. Almost all human research is Russian or Ukrainian, much of it is methodologically weak by modern standards (open-label, no placebo, small samples), and replication outside Russia is essentially absent. The 2023 receptor profiling is the most rigorous mechanistic data we have and it doesn't tell a flattering story about the parent compound. There's also no good long-term safety data beyond 3 months. Treat the clinical claims (especially the more expansive ones about memory, learning, and neuroprotection) with caution.

Dosage:

Standard anxiolytic dose: 50 mg, 2-3 times per day, total 100-150 mg/day. This is the range most users land at and it matches the Russian prescribing range for anti-asthenic and anxiolytic use

Lower starting point: 50 mg once daily for the first 2-3 days to gauge response and tolerance, especially if you're sensitive to niacin or have low blood pressure

Higher range: Up to 200-300 mg/day split across 2-3 doses for more pronounced anxiolytic effect or in the context of prolonged stress recovery. Don't push past this without a specific reason, more isn't more here

Onset and duration: 30-60 minutes to onset, effects last roughly 4-6 hours. Take the last dose by mid-afternoon if you're sensitive to anything that might disturb sleep, although picamilon is not strongly sedating

With or without food: Either works, the Russian prescribing information says food doesn't matter. On an empty stomach onset may be slightly faster

Course length: Russian protocols typically run 2-6 weeks for anxiety/asthenia and 1-3 months for cerebrovascular indications, then a 5-6 month break before repeating. Continuous daily use beyond a few months hasn't been well studied

Stacking: Pairs cleanly with stimulants (caffeine, modafinil) to take the jitter off without losing focus. Don't stack with phenibut, benzodiazepines, alcohol, or other CNS depressants, the GABAergic effects can compound. Be cautious stacking with blood pressure medications, the niacin component can drop BP further

Women: No dose adjustment needed. May be more useful in late luteal phase or perimenopause when GABA tone is naturally lower. Avoid entirely in pregnancy and breastfeeding

Older adults: Start at 50 mg once daily and titrate. Cerebrovascular indications use up to 150 mg/day for 1-2 months

Here's what you can expect:

At 50-100 mg, most people describe a quiet anxiolytic effect that comes on in 30-60 minutes, less mental noise, slightly easier social or performance situations, no slowing of thinking. Some people notice a mild warming or flushing in the first 30 minutes from the niacin component, particularly at higher doses. It's not a stimulant, it won't give you energy, but it can make stress feel more manageable and clear out the kind of low-grade nervous tension that interferes with focused work.

At 150-300 mg, the effect leans more sedating and you may notice mild relaxation in the body, slower breathing, and a more pronounced calming effect. Still not a knockout, you can function, but you may not want to take this dose before something demanding.

If you take it when you're already calm and well, you'll probably notice very little. Like most anxiolytics, the effect scales with how much anxiety or stress was there to begin with.

Don't expect a clear cognitive boost. The Russian literature claims memory and learning benefits, but those studies are in patient populations with cerebrovascular disease or alcoholism, not healthy users. In healthy adults, the noticeable effect is anxiolytic and circulatory, not cognitive sharpening.

With continuous daily use over weeks, the subjective effect tends to soften. Most users get more from it situational, before stressful events, during a stretch of high-pressure work, or as part of a 4-6 week recovery course after a period of burnout or illness, than from taking it indefinitely.

Side effects & risks:

Niacin flushing is the most common acute side effect. Warmth, redness, mild itching of the face and upper chest, particularly at doses above 100 mg. Usually mild and self-limiting, more pronounced if you're niacin-naive. Aspirin 30 minutes before can blunt it but most people don't need it

Headache and dizziness can occur, usually from the vasodilation. More common at higher doses or in people with low baseline blood pressure

Hypotension. Both niacin and GABA can lower blood pressure. If you're already on antihypertensives or you tend to run low (under 110/70), start at 50 mg and watch for lightheadedness on standing

Nausea and GI discomfort at higher doses or on an empty stomach in sensitive people

Mood paradox. A subset of users report irritability, agitation, or transient anxiety rather than calm, this is reported in the Russian product information as well. If you get this on the first or second dose, it's probably not for you

Sleep disruption if dosed too late in the day, although this is less common than with stimulants. The short half-life means evening doses usually clear before bedtime

CNS depressant interactions. Don't combine with alcohol, benzodiazepines, phenibut, opioids, or barbiturates. The Russian prescribing information specifically notes picamilon enhances the effect of opioids and shortens barbiturate sedation, both of which suggest meaningful CNS interaction

Pregnancy and breastfeeding: Contraindicated per Russian label. No human safety data

Kidney disease: Picamilon is renally excreted and contraindicated in chronic kidney disease in the Russian label. If your eGFR is below 60 you should avoid it

Hepatic concerns: Niacin at pharmacological doses can be hepatotoxic. The picamilon dose is well below niacin therapy levels but if you have liver disease or you're stacking with other hepatotoxic agents, factor this in

Regulatory and supply quality. Picamilon is a prescription drug in Russia and an unapproved drug in the US, which means most supply moves through grey-market channels. A 2016 analysis of US supplements found doses ranging from 2.7 mg to 721 mg per serving against the same label, some products contained no picamilon at all. If you're using it, sourcing from a vendor that does third-party purity testing matters more than usual

Long-term safety data is thin. Most Russian trials are 2-12 weeks. Beyond 3 months of continuous use the data essentially stops. There's no signal of serious harm at therapeutic doses but absence of evidence isn't evidence of absence

🩸

Blood markers

Blood pressure, baseline and after 1-2 weeks. Both the GABA and niacin components can lower BP. If you run low or you're on antihypertensives, you want a reference point.

Liver enzymes (ALT, AST), baseline if you plan to run continuously beyond 4 weeks or you're stacking with other compounds that load the liver. Niacin at picamilon doses is unlikely to move them, but worth knowing.

Kidney function (creatinine, eGFR), baseline. Picamilon is renally cleared and contraindicated in chronic kidney disease. If your eGFR is under 60, don't use it.

Fasting glucose and HbA1c, baseline if you're diabetic or pre-diabetic. Niacin can affect glycemic control at higher doses, again unlikely at picamilon levels but worth a baseline.

For situational use at 50-100 mg before stressful events, no specific bloodwork is needed beyond standard yearly labs. The people who actually benefit from baseline testing are those planning continuous use over a month, anyone with cardiovascular, kidney, or liver history, and anyone stacking it with other CNS-active compounds.

Prescription drug in Russia. Classified as an unapproved drug by the FDA in the US since 2015. Not approved as a dietary supplement in most Western countries.